{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:51:40Z","timestamp":1762145500241,"version":"3.44.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ucl.2019.09.014","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:41:35Z","timestamp":1574167295000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Salvage Therapy for Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"47","author":[{"given":"Dunia","family":"Khaled","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Holzbeierlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2019.09.014_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib2","first-page":"1296","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline 2016","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.014_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.014_bib5","first-page":"86","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.014_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","article-title":"Additional bacillus Calmette-Gu\u00e9rin therapy for recurrent transitional cell carcinoma after an initial complete response","volume":"49","author":"Bui","year":"1997","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.014_bib7","first-page":"220","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib8","first-page":"1124","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.014_bib9","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.014_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/BLC-159002","article-title":"Clarification of bladder cancer disease states following treatment of patients with intravesical BCG","volume":"1","author":"Lerner","year":"2015","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.014_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1756287214541798","article-title":"Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder","volume":"6","author":"Cookson","year":"2014","journal-title":"Ther Adv Urol"},{"issue":"18","key":"10.1016\/j.ucl.2019.09.014_bib12","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib13","first-page":"1200","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2019.09.014_bib14","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.014_bib16","first-page":"834","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.014_bib17","first-page":"1633","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.014_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.014_bib19","doi-asserted-by":"crossref","first-page":"35.e15-9","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.014_bib20","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.4049\/jimmunol.179.12.8418","article-title":"Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs","volume":"179","author":"Ryan","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.014_bib21","doi-asserted-by":"crossref","first-page":"670.e7-14","DOI":"10.1016\/j.urolonc.2017.07.024","article-title":"Quadruple immunotherapy of Bacillus Calmette-Guerin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"issue":"15","key":"10.1016\/j.ucl.2019.09.014_bib22","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?","volume":"24","author":"Weiss","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.014_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1464-410X.2008.08299.x","article-title":"The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?","volume":"104","author":"Wo","year":"2009","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.ucl.2019.09.014_bib24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.1991.9.9.1533","article-title":"Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy","volume":"9","author":"Fung","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.014_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/BLC-160053","article-title":"Summary and recommendations from the National Cancer Institute's clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/02656736.2016.1155760","article-title":"Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations","volume":"32","author":"Liem","year":"2016","journal-title":"Int J Hyperthermia"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.014_bib27","first-page":"1149","article-title":"Hyperthermia as treatment for bladder cancer","volume":"24","author":"Rampersaud","year":"2010","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.014_bib28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrurol.2014.52","article-title":"Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer","volume":"11","author":"Zargar","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.014_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/iju.12639","article-title":"Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?","volume":"22","author":"Kiss","year":"2015","journal-title":"Int J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.014_bib31","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib32","first-page":"1313","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.014_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.014_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Alfred Witjes","year":"2009","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.014_bib35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.014_bib36","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \"BCG failure\" non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.014_bib37","first-page":"2391","article-title":"A\u00a0first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"10","key":"10.1016\/j.ucl.2019.09.014_bib38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.014_bib39","first-page":"850","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"30","key":"10.1016\/j.ucl.2019.09.014_bib40","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.014_bib41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOU.0000000000000593","article-title":"Salvage therapeutic strategies for bacillus Calmette-Guerin failure","volume":"29","author":"Hassler","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.ucl.2019.09.014_bib42","first-page":"313","article-title":"A\u00a0Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients","volume":"4","author":"Kowalski","year":"2010","journal-title":"Drug Des Devel Ther"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2019.09.014_bib43","doi-asserted-by":"crossref","first-page":"e14576","DOI":"10.1200\/JCO.2018.36.15_suppl.e14576","article-title":"Preclinical development of ciclopirox prodrug for the treatment of non-muscle invasive and muscle invasive bladder cancer","volume":"36","author":"Weir","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2019.09.014_bib44","doi-asserted-by":"crossref","first-page":"e14705","DOI":"10.1200\/JCO.2019.37.15_suppl.e14705","article-title":"Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans","volume":"37","author":"Weir","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2019.09.014_bib45","doi-asserted-by":"crossref","first-page":"TPS2618","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2618","article-title":"Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors","volume":"36","author":"Weir","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.014_bib46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41585-019-0171-9","article-title":"Macrophage migration inhibitory factors role in genitourinary malignancies and potential for therapeutic targeting","volume":"16","author":"Penticuff","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2019.09.014_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2407-7-135","article-title":"Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice","volume":"7","author":"Taylor","year":"2006","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.014_bib48","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/carcin\/bgt239","article-title":"Macrophage Migratory Inhibitory Factor (MIF) promotes bladder cancer progression via increasing proliferation and angiogenesis","volume":"34","author":"Choudhary","year":"2013","journal-title":"Carcinogenesis"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:37:57Z","timestamp":1758807477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014319300928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0094014319300928"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.014","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage Therapy for Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}